Abstract
This review article systematically and critically summarizes the current evidence regarding desipramine for treating children and adolescents with attention deficit hyperactivity disorder (ADHD).
PRISMA guideline was used for gathering the data. The databases of PubMed/Medline and Google scholar were electronically searched. This review included controlled clinical trials investigating the efficacy of desipramine for treating children and adolescents with ADHD.
The primary outcome measure was clinical improvement measured by valid and reliable objective instruments in order to assess the severity of ADHD clinical symptoms. Adverse effects were evaluated as well.
Out of 267 titles under the study, thirty three articles mentioned desipramine for treating ADHD. Two trials met the inclusion criteria. Desipramine decreases ADHD clinical symptoms. However, there are many concerns about its safety and efficacy.
In view of serious concerns about its safety and lack of enough well-controlled trials providing strong evidence about the efficacy of desipraimine, it should be prescribed for treating children with ADHD with a high precaution, and further well-controlled trials should be performed.
Keywords: Adolescents, antidepressive agents, attention deficit hyperactivity disorder, children, desipramine, therapeutics, tricyclic.
Current Drug Safety
Title:A Systematic Review of the Efficacy and Safety of Desipramine for Treating ADHD
Volume: 8 Issue: 3
Author(s): Ahmad Ghanizadeh
Affiliation:
Keywords: Adolescents, antidepressive agents, attention deficit hyperactivity disorder, children, desipramine, therapeutics, tricyclic.
Abstract: This review article systematically and critically summarizes the current evidence regarding desipramine for treating children and adolescents with attention deficit hyperactivity disorder (ADHD).
PRISMA guideline was used for gathering the data. The databases of PubMed/Medline and Google scholar were electronically searched. This review included controlled clinical trials investigating the efficacy of desipramine for treating children and adolescents with ADHD.
The primary outcome measure was clinical improvement measured by valid and reliable objective instruments in order to assess the severity of ADHD clinical symptoms. Adverse effects were evaluated as well.
Out of 267 titles under the study, thirty three articles mentioned desipramine for treating ADHD. Two trials met the inclusion criteria. Desipramine decreases ADHD clinical symptoms. However, there are many concerns about its safety and efficacy.
In view of serious concerns about its safety and lack of enough well-controlled trials providing strong evidence about the efficacy of desipraimine, it should be prescribed for treating children with ADHD with a high precaution, and further well-controlled trials should be performed.
Export Options
About this article
Cite this article as:
Ghanizadeh Ahmad, A Systematic Review of the Efficacy and Safety of Desipramine for Treating ADHD, Current Drug Safety 2013; 8 (3) . https://dx.doi.org/10.2174/15748863113089990029
DOI https://dx.doi.org/10.2174/15748863113089990029 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Silico Binding Mode Proposed for Flavonoid Ligands of Tau Protein with Interest in Alzheimer's Disease
Current Bioactive Compounds Transglutaminases as Possible Therapeutic Targets in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Human Ascariasis: An Updated Review
Recent Patents on Inflammation & Allergy Drug Discovery Relevance of Mutations in Tau for Understanding the Tauopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Possible Physiopathological Roles of the Transglutaminase Activity in the Etiopathogenesis of Human Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Non-Antidepressant Pharmacological Treatment of Obsessive Compulsive Disorder: A Comprehensive Review
Current Clinical Pharmacology Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology Amyloid β-Peptide: The Inside Story
Current Alzheimer Research Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Pathways of Acetylcholine Synthesis, Transport and Release as Targets for Treatment of Adult-Onset Cognitive Dysfunction
Current Medicinal Chemistry Physiological Role of Peroxisome Proliferator-Activated Receptors Type Alpha on Dopamine Systems
CNS & Neurological Disorders - Drug Targets Tau Oligomerization: A Role for Tau Aggregation Intermediates Linked to Neurodegeneration
Current Alzheimer Research YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease
Current Neuropharmacology Translating Genetic Findings into Therapy in Parkinson Disease
Recent Patents on CNS Drug Discovery (Discontinued) Transglutaminase Activity as a Possible Therapeutical Target in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) An Update on the Neurochemistry of Essential Tremor
Current Medicinal Chemistry Voxel-Based Morphometry of the Human Brain: Methods and Applications
Current Medical Imaging Advantages of Structure-Based Drug Design Approaches in Neurological Disorders
Current Neuropharmacology Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design